The Blind Common Anabolic Steroid and Aromatase Inhibitor Screening is a comprehensive laboratory analysis designed to identify and quantify commonly encountered anabolic-androgenic steroids and aromatase inhibitors in raw active pharmaceutical ingredient (API) powders.
Because this is a blind analysis, there is no need to specify which substance is expected in the sample. The analysis screens for all target compounds listed below and identifies and quantifies any detected substance.
About the Target Compounds
Anabolic-androgenic steroids are synthetic derivatives of testosterone or structurally related steroid hormones. They interact with androgen receptors and produce both anabolic effects, associated with tissue and muscle growth, and androgenic effects. The screening covers testosterone and nandrolone esters, trenbolone derivatives, drostanolone esters, boldenone undecylenate, trestolone acetate, dihydroboldenone cypionate, and several other commonly encountered anabolic steroids.
Esterification modifies properties such as solubility and the rate at which a steroid is released after administration. For this reason, the panel includes multiple ester forms of testosterone, trenbolone, nandrolone, drostanolone, methenolone, and other steroid compounds.
Letrozole, anastrozole, and exemestane are aromatase inhibitors. They inhibit aromatase, the enzyme involved in estrogen biosynthesis, thereby reducing estrogen production. Letrozole and anastrozole are non-steroidal aromatase inhibitors, whereas exemestane is a steroidal inhibitor.
Key Features
- Blind screening with no need to declare the expected compound
- Identification of common anabolic steroids and aromatase inhibitors in raw API powders
- Broad panel covering steroid bases, esters, and aromatase inhibitors
- Quantification of the detected target compound
- Analysis by HPLC
- Results reported as percentage content
- Average turnaround time of 7 business days
- Minimum sample amount of 200 mg of raw powder
Analysis Parameters
- Target compounds: testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, testosterone enanthate, testosterone cypionate, testosterone decanoate, trenbolone base, trenbolone acetate, trenbolone enanthate, trenbolone hexahydrobenzylcarbonate, trestolone acetate, nandrolone phenylpropionate, nandrolone decanoate, drostanolone propionate, drostanolone enanthate, dihydroboldenone cypionate, boldenone undecylenate, letrozole, anastrozole, dihydrotestosterone (DHT), exemestane, fluoxymesterone, methandrostenolone, oxandrolone, stanozolol, 4-chlorodehydromethyltestosterone, mesterolone, methasterone, oxymetholone, methenolone acetate, methenolone enanthate, and testosterone base
- Other common names and brand names: Andriolos, Parabolan, MENT, NPP, Deca, BU, Equipoise, EQ, Parenabol, Femara, Arimidex, Aromasin, Halotestin, Halo, Anavar, Var, Winstrol, Turinabol, Proviron, Anadrol, Anapolon, Primobolan, Test E, Test C, Methandienone, Dianabol, and Dbol
- Testing method: HPLC
- Detection limit cutoff: 50%
- Result format: % [98%+, 96%+ or % value such as 94.15%]
- Minimum sample amount: 200 mg of raw powder
- Average turnaround time: 7 business days
Important Notice: The detection cutoff is 50%. Samples containing a target compound below this level may therefore fall outside the standard scope of the screening.
Optional Additional Analyses
The following optional laboratory services are available:
- Complete Raw Analytical Data
- Fentanyl Screening
- GC–MS Contamination Screening
- Heavy Metals Analysis (As, Cd, Pb, Hg)
- Additional Laboratory Report
